|Articles|June 23, 2022
How Freeze-Thaw Processes Can Be Used for the Commercialization of Cell and Gene Therapy
Author(s)Entegris
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
FDA Clears In-Vivo Gene Editing Therapy PBGENE-DMD for Duchenne Trial
2
Preclinical Study Finds Subcutaneous Nanotrastuzumab Comparable to Herceptin HYLECTA in Minipig Model
3
European Commission Approves Uplizna as Add-On Therapy for Antibody-Positive Generalized Myasthenia Gravis
4
The Clinical Execution Gap: Why Great Science Often Fails at the Trial Stage
5